Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi-modal imaging.

Weibel L, Theiler M, Howell KJ, Denton CP, Waelchli R, Atherton D, Woo P, Harper JI.

J Eur Acad Dermatol Venereol. 2020 Feb 20. doi: 10.1111/jdv.16308. [Epub ahead of print]

PMID:
32080907
2.

Predictors of progression in systemic sclerosis patients with interstitial lung disease.

Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM.

Eur Respir J. 2020 Feb 20. pii: 1902026. doi: 10.1183/13993003.02026-2019. [Epub ahead of print] Review.

PMID:
32079645
3.

Gender-related differences in systemic sclerosis.

Hughes M, Pauling JD, Armstrong-James L, Denton CP, Galdas P, Flurey C.

Autoimmun Rev. 2020 Feb 13:102494. doi: 10.1016/j.autrev.2020.102494. [Epub ahead of print] Review.

PMID:
32062031
4.

Patient experiences of digital ulcer development and evolution in systemic sclerosis.

Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A.

Rheumatology (Oxford). 2020 Feb 7. pii: keaa037. doi: 10.1093/rheumatology/keaa037. [Epub ahead of print] No abstract available.

PMID:
32031630
5.

Deep phenotyping detects a pathological CD4+ T-cell complosome signature in systemic sclerosis.

Arbore G, Ong VH, Costantini B, Denton CP, Abraham D, Placais L, Blighe K, Mitchell L, Ellis R, Heck S, Nocerino P, Woodruff TM, Kordasti S, Kemper C, Hourcade DE.

Cell Mol Immunol. 2020 Jan 23. doi: 10.1038/s41423-019-0360-8. [Epub ahead of print] No abstract available.

PMID:
31974397
6.

Improving access to digital ulcer care through nurse-led clinic: a service evaluation.

Ngcozana T, Ong VH, Denton CP.

Musculoskeletal Care. 2020 Jan 21. doi: 10.1002/msc.1433. [Epub ahead of print]

PMID:
31961999
7.

Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsets.

Moinzadeh P, Frommolt P, Franitza M, Toliat MR, Becker K, Nürnberg P, Nihtyanova SI, Ahrazoglu M, Belz D, Hunzelmann N, Abraham D, Ong VH, Mouthon L, Hesselstrand R, Denton CP, Krieg T.

J Eur Acad Dermatol Venereol. 2020 Jan 15. doi: 10.1111/jdv.16198. [Epub ahead of print] No abstract available.

PMID:
31945216
8.

Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis.

Smith V, Herrick AL, Ingegnoli F, Damjanov N, De Angelis R, Denton CP, Distler O, Espejo K, Foeldvari I, Frech T, Garro B, Gutierrez M, Gyger G, Hachulla E, Hesselstrand R, Iagnocco A, Kayser C, Melsens K, Müller-Ladner U, Paolino S, Pizzorni C, Radic M, Riccieri V, Snow M, Stevens W, Sulli A, van Laar JM, Vonk MC, Vanhaecke A, Cutolo M; EULAR Study Group on Microcirculation in Rheumatic Diseases and the Scleroderma Clinical Trials Consortium Group on Capillaroscopy.

Autoimmun Rev. 2020 Jan 10:102458. doi: 10.1016/j.autrev.2020.102458. [Epub ahead of print] Review.

9.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Stock CJW, De Lauretis A, Visca D, Daccord C, Kokosi M, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Nihtyanova S, Chua F, Maher TM, Ong V, Abraham DJ, Denton CP, Wells AU, Wain LV, Renzoni EA.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04922-6. [Epub ahead of print]

PMID:
31916109
10.

A Multi-Centre Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis.

Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A.

Arthritis Care Res (Hoboken). 2019 Dec 16. doi: 10.1002/acr.24127. [Epub ahead of print]

PMID:
31841265
11.

Aetiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.

Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J.

Am J Respir Crit Care Med. 2019 Dec 16. doi: 10.1164/rccm.201903-0563CI. [Epub ahead of print]

PMID:
31841044
12.

Challenges in systemic sclerosis trial design.

Denton CP.

Semin Arthritis Rheum. 2019 Dec;49(3S):S3-S7. doi: 10.1016/j.semarthrit.2019.09.019.

PMID:
31779848
13.

Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.

Nihtyanova SI, Sari A, Harvey JC, Leslie A, Derrett-Smith EC, Fonseca C, Ong VH, Denton CP.

Arthritis Rheumatol. 2019 Nov 4. doi: 10.1002/art.41153. [Epub ahead of print]

PMID:
31682743
14.

Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.

Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, Valentini G, Matucci Cerinic M, Distler O, Cozzi F, Carreira P, Allanore Y, Müller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirják L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA; EUSTAR co-authors .

Rheumatology (Oxford). 2019 Nov 4. pii: kez486. doi: 10.1093/rheumatology/kez486. [Epub ahead of print]

PMID:
31680161
15.

GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.

López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeón CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B; European Scleroderma Group†, Proudman S, Stevens W, Nikpour M; Australian Scleroderma Interest Group (ASIG), Vyse T, Herrick AL, Worthington J, Denton CP, Allanore Y, Brown MA, Radstake TRDJ, Fonseca C, Chang HY, Mayes MD, Martin J.

Nat Commun. 2019 Oct 31;10(1):4955. doi: 10.1038/s41467-019-12760-y.

16.

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).

Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grünig E.

Arthritis Res Ther. 2019 Oct 26;21(1):217. doi: 10.1186/s13075-019-1981-0.

17.

Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern".

Smith V, Vanhaecke A, Herrick AL, Distler O, Guerra MG, Denton CP, Deschepper E, Foeldvari I, Gutierrez M, Hachulla E, Ingegnoli F, Kubo S, Müller-Ladner U, Riccieri V, Sulli A, van Laar JM, Vonk MC, Walker UA, Cutolo M; EULAR Study Group on Microcirculation in Rheumatic Diseases.

Autoimmun Rev. 2019 Nov;18(11):102394. doi: 10.1016/j.autrev.2019.102394. Epub 2019 Sep 11.

18.

Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.

Dhaliwal K, Griffin MF, Salinas S, Howell K, Denton CP, Butler PEM.

Clin Rheumatol. 2019 Dec;38(12):3669-3676. doi: 10.1007/s10067-019-04762-4. Epub 2019 Sep 3.

PMID:
31482318
19.

Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction.

Bageghni SA, Hemmings KE, Yuldasheva NY, Maqbool A, Gamboa-Esteves FO, Humphreys NE, Jackson MS, Denton CP, Francis S, Porter KE, Ainscough JF, Pinteaux E, Drinkhill MJ, Turner NA.

JCI Insight. 2019 Aug 8;5. pii: 125074. doi: 10.1172/jci.insight.125074.

20.

Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.

Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, Matucci-Cerinic M, Guiducci S, Distler O, Maurer B, Avouac J, Tarner IH, Frerix M, Riemekasten G, Siegert E, Czirják L, Lóránd V, Denton CP, Nihtyanova S, Walker UA, Jaeger VK, Del Galdo F, Abignano G, Ananieva LP, Gherghe AM, Mihai C, Henes JC, Schmeiser T, Vacca A, Moiseev S, Foeldvari I, Gabrielli A, Krummel-Lorenz B, Rednic S, Allanore Y, Müeller-Ladner U.

Ann Rheum Dis. 2019 Nov;78(11):1576-1582. doi: 10.1136/annrheumdis-2019-215486. Epub 2019 Aug 7.

PMID:
31391176
21.

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.

Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE.

Arthritis Rheumatol. 2020 Jan;72(1):125-136. doi: 10.1002/art.41055. Epub 2019 Dec 10.

PMID:
31342624
22.

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.

Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V.

Curr Med Res Opin. 2019 Nov;35(11):2015-2024. doi: 10.1080/03007995.2019.1647040. Epub 2019 Aug 2.

PMID:
31328965
23.

Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis.

Almadori A, Griffin M, Ryan CM, Hunt DF, Hansen E, Kumar R, Abraham DJ, Denton CP, Butler PEM.

PLoS One. 2019 Jul 17;14(7):e0218068. doi: 10.1371/journal.pone.0218068. eCollection 2019.

24.

Sidestream Dark Field (SDF) imaging of oral microcirculation in the assessment of systemic sclerosis.

Sha M, Griffin M, Denton CP, Butler PE.

Microvasc Res. 2019 Nov;126:103890. doi: 10.1016/j.mvr.2019.103890. Epub 2019 Jul 1.

PMID:
31271765
25.

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.

Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, Matucci-Cerinic M, de Oliveira Pena J, Pope JE, Distler O; EUSTAR Collaborators; EUSTAR Collaborators (numerical order of centres).

Ann Rheum Dis. 2019 Sep;78(9):1242-1248. doi: 10.1136/annrheumdis-2019-215145. Epub 2019 Jun 21.

26.

Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease.

Wells A, Devaraj A, Renzoni EA, Denton CP.

Semin Respir Crit Care Med. 2019 Apr;40(2):184-193. doi: 10.1055/s-0039-1684020. Epub 2019 May 28.

PMID:
31137059
27.

Pulmonary Complications of Connective Tissue Disease.

Wells A, Denton CP.

Semin Respir Crit Care Med. 2019 Apr;40(2):145-146. doi: 10.1055/s-0039-1688716. Epub 2019 May 28. No abstract available.

PMID:
31137055
28.

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.

Blagojevic J, Abignano G, Avouac J, Cometi L, Frerix M, Bellando-Randone S, Guiducci S, Bruni C, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Czirják L, Denton CP, Distler O, Allanore Y, Müller-Ladner U, Moggi-Pignone A, Matucci-Cerinic M, Del Galdo F; EUSTAR co-workers.

Clin Rheumatol. 2020 Jan;39(1):27-36. doi: 10.1007/s10067-019-04564-8. Epub 2019 May 20.

PMID:
31111363
29.

Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis.

Denton CP, Murray C.

Arthritis Res Ther. 2019 Mar 27;21(1):81. doi: 10.1186/s13075-019-1872-4.

30.

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.

Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators.

Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9.

31.

Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis.

Campochiaro C, Lytton S, Nihtyanova S, Fuchs D, Ong VH, Denton CP.

Clin Immunol. 2019 Feb;199:18-24. doi: 10.1016/j.clim.2018.12.009. Epub 2019 Feb 14.

PMID:
30771500
32.

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.

Blagojevic J, Bellando-Randone S, Abignano G, Avouac J, Cometi L, Czirják L, Denton CP, Distler O, Frerix M, Guiducci S, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Allanore Y, Müller-Ladner U, Del Galdo F, Matucci-Cerinic M; EUSTAR co-workers.

Arthritis Res Ther. 2019 Jan 24;21(1):35. doi: 10.1186/s13075-019-1822-1.

33.

Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure.

Nagel C, Marra AM, Benjamin N, Blank N, Cittadini A, Coghlan G, Distler O, Denton CP, Egenlauf B, Fiehn C, Fischer C, Harutyunova S, Hoeper MM, Lorenz HM, Xanthouli P, Bossone E, Grünig E.

Arthritis Rheumatol. 2019 May;71(5):805-816. doi: 10.1002/art.40814. Epub 2019 Apr 10.

PMID:
30615302
34.

Autoimmunity and immunodeficiency at the crossroad: autoimmune disorders as the presenting feature of selective IgM deficiency.

Campochiaro C, Atay S, Clark KEN, Ong V, Denton CP.

BMJ Case Rep. 2019 Jan 3;12(1). pii: e223180. doi: 10.1136/bcr-2017-223180.

PMID:
30610030
35.

A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility.

González-Serna D, Carmona EG, Ortego-Centeno N, Simeón CP, Solans R, Hernández-Rodríguez J, Tolosa C, Castañeda S, Narváez J, Martinez-Valle F; European GCA Consortium; European Scleroderma Group, Witte T, Neumann T, Holle J, Beretta L, Boiardi L, Emmi G, Cimmino MA, Vaglio A, Herrick AL, Denton CP, Salvarani C, Cid MC, Morgan AW, Fonseca C, González-Gay MA, Martín J, Márquez A.

PLoS One. 2018 Dec 26;13(12):e0209343. doi: 10.1371/journal.pone.0209343. eCollection 2018.

36.

Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801913. doi: 10.1183/13993003.01913-2018. Print 2019 Jan.

37.

Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis.

Bruni C, Ngcozana T, Braschi F, Pucci T, Piemonte G, Benelli L, Poli M, Suliman YA, Guiducci S, Bellando-Randone S, Balduzzi S, Grotts J, Denton CP, Rasero L, Montecucco C, Furst DE, Matucci-Cerinic M.

J Rheumatol. 2019 Jun;46(6):603-608. doi: 10.3899/jrheum.171486. Epub 2018 Nov 15.

PMID:
30442833
38.

Author Correction: Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Nov;14(11):682. doi: 10.1038/s41584-018-0108-3.

PMID:
30317249
39.

European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.

Abignano G, Blagojevic J, Bissell LA, Dumitru RB, Eng S, Allanore Y, Avouac J, Bosello S, Denton CP, Distler O, Ferraccioli G, Jordan S, Matucci-Cerinic M, Ong V, Messenger M, Hutchinson M, Buch MH, Emery P, Del Galdo F.

Rheumatology (Oxford). 2019 Feb 1;58(2):254-259. doi: 10.1093/rheumatology/key271.

40.

Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor-ß.

Chaigne B, Clary G, Le Gall M, Dumoitier N, Fernandez C, Lofek S, Chafey P, Moinzadeh P, Krieg T, Denton CP, Mouthon L.

Proteomics Clin Appl. 2019 Jul;13(4):e1800069. doi: 10.1002/prca.201800069. Epub 2018 Sep 6.

PMID:
30141531
41.

Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Sep;14(9):511-527. doi: 10.1038/s41584-018-0062-0. Review. Erratum in: Nat Rev Rheumatol. 2018 Nov;14(11):682.

PMID:
30111804
42.

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S.

Rheumatology (Oxford). 2019 Apr 1;58(4):567-579. doi: 10.1093/rheumatology/key151. Review.

43.

Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design.

Hughes M, Tracey A, Bhushan M, Chakravarty K, Denton CP, Dubey S, Guiducci S, Muir L, Ong V, Parker L, Pauling JD, Prabu A, Rogers C, Roberts C, Herrick AL.

J Scleroderma Relat Disord. 2018 Jun 1;3(2):170-174. doi: 10.1177/2397198318764796. Epub 2018 Mar 27.

44.

Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?

Hughes M, Murray A, Denton CP, Herrick AL.

Med Hypotheses. 2018 Jul;116:101-104. doi: 10.1016/j.mehy.2018.04.024. Epub 2018 May 2.

PMID:
29857890
45.

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.

Ann Rheum Dis. 2018 Sep;77(9):1362-1371. doi: 10.1136/annrheumdis-2018-213031. Epub 2018 May 31.

46.

Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study.

Jaeger VK, Valentini G, Hachulla E, Cozzi F, Distler O, Airó P, Czirják L, Allanore Y, Siegert E, Rosato E, Matucci-Cerinic M, Caimmi C, Henes J, Carreira PE, Smith V, Del Galdo F, Denton CP, Ullman S, De Langhe E, Riccieri V, Alegre-Sancho JJ, Rednic S, Müller-Ladner U, Walker UA; EUSTAR coauthors.

Arthritis Rheumatol. 2018 Nov;70(11):1829-1834. doi: 10.1002/art.40557. Epub 2018 Sep 24.

47.

Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.

Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, Agueusop I, Denton CP, Khanna D.

Arthritis Rheumatol. 2018 Oct;70(10):1634-1643. doi: 10.1002/art.40547. Epub 2017 Nov 6.

48.

Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism.

Bageghni SA, Hemmings KE, Zava N, Denton CP, Porter KE, Ainscough JFX, Drinkhill MJ, Turner NA.

FASEB J. 2018 Sep;32(9):4941-4954. doi: 10.1096/fj.201701455RR. Epub 2018 Mar 30.

49.

Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.

Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, Marra AM, Benjamin N, Fischer C, Grünig E.

Eur Respir J. 2018 Apr 4;51(4). pii: 1701197. doi: 10.1183/13993003.01197-2017. Print 2018 Apr.

50.

The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.

Dhaliwal K, Griffin M, Denton CP, Butler PEM.

BMJ Case Rep. 2018 Mar 9;2018. pii: bcr-2017-219348. doi: 10.1136/bcr-2017-219348.

PMID:
29525756

Supplemental Content

Loading ...
Support Center